Abstract
The identification of HPV as the cause of cervical cancer has changed the information required for surveillance. HPV prevalence and screening uptake worldwide are now necessary to describe the epidemiology of this cancer.
In low-income countries cervical cancer incidence varies from low to very high levels and is strongly influenced by virus prevalence. In high-income countries, instead, incidence is low and little influenced by the virus prevalence, thanks to screening.
The European Guidelines currently recommend Pap test every 3-5 years starting at age 22-30 and stopping at age 60-65. HPV testing is now limited to triage of borderline lesions? and to post-CIN follow up. Pilot studies evaluating HPV testing as primary test are recommended.
Future governmental agency Guidelines in Europe will probably include HPV testing as viable for primary screening, with cytology triage for HPV-positive women (those positive to cytology will be directly referred to colposcopy, those negative will repeat HPV at one year. Persistence of HPV positivity will refer to colposcopy directly, clearance to regular screening). The interval after an HPV-negative test should be at least 5 years and starting age should be age 30/35. Pap test is still recommended for women under 30.
Keywords: HPV, cervical cancer, screening, vaccination, HPV testing, Pap Test, cytology, colposcopy, surveillance, lesions
Current Pharmaceutical Design
Title:The Present and Future of Cervical Cancer Screening Programmes in Europe
Volume: 19 Issue: 8
Author(s): Paolo Giorgi Rossi and Guglielmo Ronco
Affiliation:
Keywords: HPV, cervical cancer, screening, vaccination, HPV testing, Pap Test, cytology, colposcopy, surveillance, lesions
Abstract: The identification of HPV as the cause of cervical cancer has changed the information required for surveillance. HPV prevalence and screening uptake worldwide are now necessary to describe the epidemiology of this cancer.
In low-income countries cervical cancer incidence varies from low to very high levels and is strongly influenced by virus prevalence. In high-income countries, instead, incidence is low and little influenced by the virus prevalence, thanks to screening.
The European Guidelines currently recommend Pap test every 3-5 years starting at age 22-30 and stopping at age 60-65. HPV testing is now limited to triage of borderline lesions? and to post-CIN follow up. Pilot studies evaluating HPV testing as primary test are recommended.
Future governmental agency Guidelines in Europe will probably include HPV testing as viable for primary screening, with cytology triage for HPV-positive women (those positive to cytology will be directly referred to colposcopy, those negative will repeat HPV at one year. Persistence of HPV positivity will refer to colposcopy directly, clearance to regular screening). The interval after an HPV-negative test should be at least 5 years and starting age should be age 30/35. Pap test is still recommended for women under 30.
Export Options
About this article
Cite this article as:
Giorgi Rossi Paolo and Ronco Guglielmo, The Present and Future of Cervical Cancer Screening Programmes in Europe, Current Pharmaceutical Design 2013; 19 (8) . https://dx.doi.org/10.2174/1381612811319080016
DOI https://dx.doi.org/10.2174/1381612811319080016 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Proteasome Inhibitors in Cancer Therapy
Current Drug Targets Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of XRCC4 in Carcinogenesis and Anticancer Drug Discovery
Recent Patents on Anti-Cancer Drug Discovery Anti-Epidermal Growth Factor Receptor Strategies to Enhance Radiation Action
Current Medicinal Chemistry - Anti-Cancer Agents Targeting Cancer Cells with Photoactive Silica Nanoparticles
Current Pharmaceutical Design Destabilizing Aneuploidy by Targeting Cell Cycle and Mitotic Checkpoint Proteins in Cancer Cells
Current Drug Targets Serine Protease Inhibitors and T Lymphocyte Immunity
Current Immunology Reviews (Discontinued) Encountering and Advancing Through Antiangiogenesis Therapy for Gliomas
Current Pharmaceutical Design Management of Locally Advanced Cancer Cervix an Indian Perspective
Reviews on Recent Clinical Trials Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Delivery of Intracellular-Acting Biologics in Pro-Apoptotic Therapies
Current Pharmaceutical Design Inherited Copper Transport Disorders: Biochemical Mechanisms, Diagnosis, and Treatment
Current Drug Metabolism Targeting the Immune System in Cancer
Current Pharmaceutical Biotechnology Magnetic Hyperthermia with Magnetic Nanoparticles: A Status Review
Current Topics in Medicinal Chemistry The Capsaicin Paradox: Pain Relief by an Algesic Agent
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Targeting ATP7A to Increase the Sensitivity of Neuroblastoma Cells to Retinoid Therapy
Current Cancer Drug Targets Osteogenic Peptides in Bone Regeneration
Current Pharmaceutical Design Immune Checkpoint Inhibitors in the Treatment of Cancer
Current Reviews in Clinical and Experimental Pharmacology The Epidemiology and Health Effects of Tobacco Use
Current Pediatric Reviews Promises of Lipid-based Drug Delivery Systems in the Management of Breast Cancer
Current Pharmaceutical Design